NMD Pharma initiates Phase I safety, tolerability and pharmacokinetics study of NMD1343
NMD Pharma initiates Phase I safety, tolerability and pharmacokinetics studyof NMD1343
NMD1343 is a novel small molecule inhibitor of the muscle-specific chloride ion channel, the ClC-1 ion channel, and NMD Pharma’s second clinical development candidate
Aarhus, Denmark, 23 May2023 – NMD Pharma A/S, a clinical-stage biotech company developing first-in-class, small molecule ClC-1 inhibitors for neuromuscular disorders, today announces that the first healthy volunteers have been dosed at the study site in London, UK.
The Phase I clinical trial is a randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability, and pharmacokinetics of oral NMD1343 in healthy male and female volunteers. All participants will be screened up to four weeks prior to dosing and each cohort of eight healthy volunteers will be randomized to receive, initially, either a single dose of NMD1343 or a matching placebo. The study was reviewed and approved by the Medicines & Healthcare products Regulatory Agency (MHRA).
Jorge A. Quiroz, SVP and Chief Medical Officer NMD Pharmacommented:“It is an exciting time at NMD Pharma, now launching our second ClC-1 inhibitor NMD1343 that, with a differentiated profile compared to otherdevelopment candidates in our pipeline,could be beneficial for patients with a range of rare neuromuscular diseases.”
Thomas Holm Pedersen, Chief Executive Officer of NMD Pharma, said: “We are very pleased to announce that the first healthy subject has been dosed in this Phase I study with NMD1343.NMD Pharma is focused on thedevelopment of novel first-in-class therapies for severe neuromuscular disorders,and the initiation of this study expands our clinical pipeline andour vision of delivering life-transforming therapies for those patients and their families.”
In addition to NMD1343, NMD Pharma is also developing NMD670, a first-in-class small molecule inhibitor of the muscle specific chloride ion channel, the ClC-1 ion channel. NMD Pharma has pre-clinically demonstrated that ClC-1 inhibition can enhance neuromuscular transmission and, ultimately, skeletal muscle function and NMD670 has already demonstrated positive results in a Phase I and proof of mechanism study in patients with myasthenia gravis confirming safety, tolerability and initial efficacy data in subjects suffering from neuromuscular disorders.
NMD Pharma A/S
Thomas Holm Pedersen, CEO
Consilium Strategic Communications
Mary-Jane Elliott / Ashley Tapp / Lindsey Neville
Tel: +44 (0)20 3709 5700
About NMD Pharma
NMD Pharma A/S, is a clinical-stage biotech company leading in the development of novel first-in-class therapies for severe neuromuscular disorders. The Company was incorporated as a spin-out from Aarhus University, Denmark in 2015 and was founded on more than 15 years of muscle physiology research with a focus on regulation of skeletal muscle excitability under physical activity. NMD Pharma has built a world-leading muscle electrophysiology platform leveraging its in-depth know-how of muscle physiology and muscular disorders and is developing a pipeline of ClC-1 inhibitors for the treatment of patients with neuromuscular disorders including myasthenia gravis, spinal muscular atrophy and Charcot-Marie Tooth. Positive top line data reported from a Phase I and proof of mechanism study of lead program NMD670 in myasthenia gravis has provided clinical validation of ClC-1 inhibition to restore neuromuscular function. NMD Pharma has raised ~€80 million from investors including Novo Holdings, Lundbeckfonden BioCapital, INKEF Capital, Roche Venture Fund, and Jeito Capital. Find out more about us online at http://www.nmdpharma.com/.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Webull Australia avails Cboe US Options2.6.2023 01:00:00 CEST | Press release
SYDNEY, Australia, June 02, 2023 (GLOBE NEWSWIRE) -- Webull Securities (Australia) Pty. Ltd. ("Webull AU"), an Australian brokerage firm licensed by the Australian Securities Investment Commission that operates on the popular Webull trading platform, has announced the launch of a suite of Cboe Global Markets (Cboe) US index options on 23 April 2023. This new offering allows Australian retail investors access to cash-settled index options trading through Cboe’s popular US options suite, including the S&P 500 Index (SPX) options, Cboe Volatility Index (VIX) options and Mini-S&P 500 Index (XSP) options. The addition is an extension to Webull AU's existing US options offering and furthers Cboe’s and Webull’s commitment to offering new and innovative products and education resources to retail investors across the globe. The S&P 500 Index is the global benchmark of large-cap US equities and the VIX Index is the world's premier gauge of expected US equity market volatility. The introduction o
Westport Announces Effective Date of Share Consolidation1.6.2023 23:00:00 CEST | Press release
VANCOUVER, British Columbia, June 01, 2023 (GLOBE NEWSWIRE) -- Westport Fuel Systems Inc. ("Westport" or the "Company") (TSX:WPRT / Nasdaq: WPRT) a global leader in low-emissions alternative fuel transportation technologies is pleased to announce, further to its April 26, 2023 press release, the completion of the Company's proposed consolidation of its common shares ("Common Shares") on the basis of (1) new post-consolidation Common Share for every ten (10) existing pre-consolidation Common Shares (the "Consolidation"). As of the date hereof, and following the Consolidation, there are 17,174,972 Common Shares issued and outstanding. Immediately prior to the Consolidation, the Company had 171,751,409 Common Shares issued and outstanding. No fractional Common Shares will be issued pursuant to the Consolidation and any fractional shares that would otherwise be issued will be rounded down to the nearest whole Common Share. A letter of transmittal with respect to the Consolidation is being
Constellation Brands to Report First Quarter Fiscal 2024 Financial Results; Host Conference Call June 30, 20231.6.2023 22:30:41 CEST | Press release
VICTOR, N.Y., June 01, 2023 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE: STZ), a leading beverage alcohol company, announced today it will report financial results for its first quarter ended May 31, 2023, on Friday, June 30, 2023, before the open of the U.S. markets. A conference call to discuss the financial results and outlook will be hosted by President and Chief Executive Officer, Bill Newlands, and Executive Vice President and Chief Financial Officer, Garth Hankinson, at 10:30 a.m. EDT, June 30, 2023. The conference call can be accessed by dialing +1-877-407-9121 and entering conference identification number 13739041, beginning at 10:20 a.m. EDT. A live, listen-only webcast of the conference call will be available on the company’s investor relations website at ir.cbrands.com under the News & Events section. When the call begins, financial information discussed on the conference call, and reconciliations of reported GAAP financial measures with comparable and other non-GA
Amlan International Names Beijing Zhongnong Pasture Biotechnology Co., Ltd. as Master Distributor in China1.6.2023 22:03:55 CEST | Press release
CHICAGO, June 01, 2023 (GLOBE NEWSWIRE) -- Amlan® International, the animal health business of Oil-Dri® Corporation of America and a global leader in mineral-based feed additives that optimize the intestinal health of poultry and livestock, is proud to announce its strategic restructuring plans for the China business. To streamline distribution and increase efficiency, Amlan has chosen Beijing Zhongnong Pasture Biotechnology Co., Ltd. as its master distributor in China. The strategic decision recognizes the significance of the Chinese market and Amlan’s successful longstanding partnership with Zhongnong. In 2021, China had the world’s largest swine meat production, 53 million MT, producing 44% of global production. Additionally, China was the world’s second largest broiler meat producer, producing 14.7 million MT, and the world’s third largest milk producer, producing 36.8 million MT in the same year. With nearly 20 years of experience serving the Chinese feed and farming industry, Zho
EURO Ressources: Results of the annual ordinary general meeting of shareholders held on May 17, 20231.6.2023 21:45:00 CEST | Press release
NEWS RELEASEParis: EUR RESULTS OF THE ANNUAL ORDINARY GENERAL MEETING OF SHAREHOLDERS HELD ON MAY 17, 2023 PARIS, France, June 1, 2023: EURO Ressources S.A. (EURO) (Paris: EUR) today announced the results of the annual ordinary general meeting of shareholders held on Wednesday, May 17, 2023. A total of 32 shareholders were present, represented or have voted by correspondance, holding 56,933,262 common shares of the 62,491,281 common shares making up the stated capital, which represent approximately 91.105 % of the share capital, satisfying the required quorum for the resolutions related to the ordinary general meeting of shareholders. All of the resolutions were passed, except resolution 3 which was rejected. The results of each resolution are detailed as follows: ResolutionTotal number of votes castNumber of sharesVotes In favour / %Votes Against / %Votes AbstainingApproval of the Company's financial statements for 2022 fiscal year (Resolution 1)113,336,40156,933,262112,316,844 99.10